Prostate stereotactic body radiotherapy with simultaneous integrated boost: Which is the best planning method?

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Tree, Alison ^a   Jones, Caroline ^a   Sohaib, Aslam ^a   Khoo, Vincent ^a,b   van As, Nicholas ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Focal boost; Prostate cancer; Stereotactic body radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; HUMAN; MALE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; COMPUTER ASSISTED RADIOTHERAPY; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; RADIOSURGERY;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84884755217     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-228     Document Type: Article

References (49)

1. Al-Mamgani A, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72(4):980-8. 10.1016/j.ijrobp.2008.02.073, 18495377.
2. Dearnaley DP, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8(6):475-87. 10.1016/S1470-2045(07)70143-2, 17482880.
3. Pollack A, et al. Prostate cancer radiation dose response: results of the M D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53(5):1097-105. 10.1016/S0360-3016(02)02829-8, 12128107.
4. Zelefsky MJ, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71(4):1028-33. 10.1016/j.ijrobp.2007.11.066, 18280056.
5. Brenner DJ, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1):6-13. 10.1016/S0360-3016(01)02664-5, 11777617.
6. Miralbell R, et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82(1):e17-24. 10.1016/j.ijrobp.2010.10.075, 21324610.
7. Dasu A, Toma-Dasu I. Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol 2012, 51(8):963-74. 10.3109/0284186X.2012.719635, 22966812.
8. Dearnaley D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13(1):43-54. 10.1016/S1470-2045(11)70293-5, 22169269.
9. Arcangeli G, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78(1):11-8. 10.1016/j.ijrobp.2009.07.1691, 20047800.
10. Yeoh EE, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81(5):1271-8. 10.1016/j.ijrobp.2010.07.1984, 20934277.
11. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3. 10.1186/1748-717X-6-3, 3022740, 21219625.
12. Katz AJ, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1. 10.1186/1471-2490-10-1, 2831888, 20122161.
13. King CR, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73(4):1043-8. 10.1016/j.ijrobp.2008.05.059, 18755555.
14. Meier R, et al. Stereotactic body radiotherapy for intermediate-risk organ-confined prostate cancer: interim toxicity and quality of life outcomes from a multi-institutional study. Int J Radiat Oncol Biol Phys 2012, 84(3):S148.
15. Arrayeh E, et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012, 82(5):e787-93. 10.1016/j.ijrobp.2011.11.030, 3285390, 22331003.
16. Cellini N, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53(3):595-9. 10.1016/S0360-3016(02)02795-5, 12062602.
17. Fuller DB, et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008, 70(5):1588-97. 10.1016/j.ijrobp.2007.11.067, 18374232.
18. The PACE trial 2013, http://www.clinicaltrials.gov/ct2/show/NCT01584258.
19. Davis BJ, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999, 85(12):2630-7. 10.1002/(SICI)1097-0142(19990615)85:12<2630::AID-CNCR20>3.0.CO;2-L, 10375112.
20. Chao KK, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65(4):999-1007. 10.1016/j.ijrobp.2006.02.039, 16750320.
21. McNair HA, et al. A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2008, 71(1):41-50. 10.1016/j.ijrobp.2007.09.002, 17996391.
22. Adamson J, Wu Q. Inferences about prostate intrafraction motion from pre- and posttreatment volumetric imaging. Int J Radiat Oncol Biol Phys 2009, 75(1):260-7. 10.1016/j.ijrobp.2009.03.007, 2730426, 19515507.
23. Beltran C, Herman MG, Davis BJ. Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods. Int J Radiat Oncol Biol Phys 2008, 70(1):289-95. 10.1016/j.ijrobp.2007.08.040, 17919837.
24. Kupelian P, et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67(4):1088-98. 10.1016/j.ijrobp.2006.10.026, 17187940.
25. Schmuecking M, et al. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?. Int J Radiat Biol 2009, 85(9):814-24. 10.1080/09553000903090027, 19701842.
26. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 2006, 50(6):1163-1174. discussion 1175, 10.1016/j.eururo.2006.06.025, 16842903.
27. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 2009, 6(4):191-203. 10.1038/nrurol.2009.27, 3520096, 19352394.
28. Testa C, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007, 244(3):797-806. 10.1148/radiol.2443061063, 17652190.
29. Tamada T, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol 2011, 197(3):664-70. 10.2214/AJR.10.5923, 21862809.
30. Riches SF, et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 2009, 193(6):1583-91. 10.2214/AJR.09.2540, 19933651.
31. Kozlowski P, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 2006, 24(1):108-13. 10.1002/jmri.20626, 16767709.
32. Selnaes KM, et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol 2012, 47(11):624-33. 10.1097/RLI.0b013e318263f0fd, 23011187.
33. Afaq A, et al. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int 2011, 108(11):1716-22. 10.1111/j.1464-410X.2011.10256.x, 21631696.
34. van Dorsten FA, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004, 20(2):279-87. 10.1002/jmri.20113, 15269954.
35. Groenendaal G, et al. Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone. Int J Radiat Oncol Biol Phys 2012, 82(3):e537-44. 10.1016/j.ijrobp.2011.07.021, 22197085.
36. Groenendaal G, et al. The effect of hormonal treatment on conspicuity of prostate cancer: implications for focal boosting radiotherapy. Radiother Oncol 2012, 103(2):233-8. 10.1016/j.radonc.2011.12.007, 22265733.
37. Pinkawa M, et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 2010, 186(11):600-6. 10.1007/s00066-010-2122-5, 20936457.
38. Seppala J, et al. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol 2009, 93(2):234-40. 10.1016/j.radonc.2009.08.010, 19766336.
39. Housri N, et al. Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80(2):614-20. 10.1016/j.ijrobp.2010.06.050, 3580994, 20932672.
40. Tree A, Khoo VS, van As N. To deliver a focal boost during whole prostate gland irradiation using Cyberknife. Radiother Oncol 2012, 103(s1):s494.
41. Ling CC, et al. Dose-rate effects in external beam radiotherapy redux. Radiother Oncol 2010, 95(3):261-8. 10.1016/j.radonc.2010.03.014, 20363041.
42. Litzenberg DW, et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2006, 65(2):548-53. 10.1016/j.ijrobp.2005.12.033, 16545919.
43. Langen KM, et al. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 2008, 71(4):1084-90. 10.1016/j.ijrobp.2007.11.054, 18280057.
44. Lips IM, et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials 2011, 12:255. 10.1186/1745-6215-12-255, 3286435, 22141598.
45. Fonteyne V, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72(3):799-807. 10.1016/j.ijrobp.2008.01.040, 18407430.
46. De Meerleer G, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 2005, 75(3):325-33. 10.1016/j.radonc.2005.04.014, 15967524.
47. Pinkawa M, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol 2012, 7:14. 10.1186/1748-717X-7-14, 3299580, 22289620.
48. Ippolito E, et al. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol 2012, 35(2):158-62. 10.1097/COC.0b013e318209cd8f, 21336090.
49. Dose EscaLation to intraprostatic tumour nodules in localisEd prostATE cancer: A phase II study examining the toxicity and feasibility of a dose escalated boost to a magnetic resonance imaging identified tumour nodule or nodules in localised prostate cancer [Accessed 9th September 2013]; Available from: http://www.controlled-trials.com/ISRCTN04483921.